Advertisement

Annals of Hematology

, Volume 86, Issue 8, pp 565–568 | Cite as

Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas

  • Luigi RigacciEmail author
  • Luca Nassi
  • Marco Puccioni
  • Silvia Mappa
  • Ennio Polito
  • Serena Dal Pozzo
  • Renato Alterini
  • Valentina Carrai
  • Benedetta Puccini
  • Alberto Bosi
Original Article

Abstract

Ocular adnexal lymphomas (OALs) are typically low-grade lymphomas and are largely represented by marginal-zone lymphomas (EMZL). Radiotherapy is the treatment of choice but is frequently associated to local complications. We investigated the association of chlorambucil and rituximab as first-line treatment for primary OALs. Nine consecutive, newly diagnosed OALs patients (eight with a EMZL, one with a follicular lymphoma) with a median age of 78 years were treated with this combination. Eight patients were in stage I-A, and one was in stage IV-A; all patients had low LDH values. Eight patients (89%) obtained a complete remission and one a partial response. All completed the treatment without significant toxicities. After a median follow up of 25 months, all patients are alive; no progressions or late toxicities were observed. Rituximab in combination with chlorambucil proved to be a feasible option as first-line treatment for OALs because of its feasibility and the absence of toxicity and local sequelae.

Keywords

Ocular adnexal lymphoma Low-grade lymphoma Chemotherapy Immunotherapy 

References

  1. 1.
    Decaudin D, de Cremoux P, Vincent-Salomon A, Dendale R, Lumbroso-Le Rouic L (2006) Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood 108:1451–1460PubMedCrossRefGoogle Scholar
  2. 2.
    Meunier J, Lumbroso-Le Rouic L, Vincent-Salomon A, Dendale R, Asselain B, Arnaud P, Fourquet A, Desjardins L, Plancher C, Validire P, Chaoui D, Levy C, Decaudin D (2004) Ophthalmologic and intraocular non-Hodgkin’s lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors. Hematol Oncol 22:143–158PubMedCrossRefGoogle Scholar
  3. 3.
    Ferreri AJ, Ponzoni M, Guidoboni M, De Conciliis C, Resti AG, Mazzi B, Lettini AA, Demeter J, Dell’Oro S, Doglioni C, Villa E, Bogliocchi M, Dolcetti R (2005) Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol 23:5067–5073PubMedCrossRefGoogle Scholar
  4. 4.
    Grunberger B, Hauff W, Lukas J, Wohrer S, Zielinski CC, Streubel B, Chott A, Raderer M (2006) ‘Blind’ antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa. Ann Oncol 17:484–487PubMedCrossRefGoogle Scholar
  5. 5.
    Bolek TW, Moyses HM, Marcus RB Jr, Gorden L 3rd, Maiese RL, Almasri NM, Mendenhall NP (1999) Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys 44:31–36PubMedCrossRefGoogle Scholar
  6. 6.
    Bhatia S, Paulino AC, Buatti JM, Mayr NA, Wen BC (2002) Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys 54:818–823PubMedCrossRefGoogle Scholar
  7. 7.
    Cho EY, Han JJ, Ree HJ, Ko YH, Kang YK, Ahn HS, Ahn SD, Park CJ, Huh J (2003) Clinicopathologic analysis of ocular adnexal lymphomas: extranodal marginal zone B-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients. Am J Hematol 73:87–96PubMedCrossRefGoogle Scholar
  8. 8.
    Ben Simon GJ, Cheung N, McKelvie P, Fox R, McNab AA (2006) Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit. Ophthalmology 113:1209–1213PubMedCrossRefGoogle Scholar
  9. 9.
    Conconi A, Martinelli G, Thieblemont C, Ferreri AJM, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell’Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E (2003) Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 102:2741–2745PubMedCrossRefGoogle Scholar
  10. 10.
    Raderer M, Jager G, Brugger S, Puspok A, Fiebiger W, Drach J, Wotherspoon A, Chott A (2003) Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 65:306–310PubMedCrossRefGoogle Scholar
  11. 11.
    Zinzani PL, Alinari L, Stefoni V, Loffredo A, Pichierri P, Polito E (2005) Rituximab in primary conjunctival lymphoma. Leuk Res 29:107–108PubMedCrossRefGoogle Scholar
  12. 12.
    Benetatos L, Alymara V, Asproudis I, Bourantas KL (2006) Rituximab as first line treatment for MALT lymphoma of extraocular muscles. Ann Hematol 85:625–626PubMedCrossRefGoogle Scholar
  13. 13.
    Ferreri AJM, Ponzoni M, Martinelli G, Muti G, Guidoboni M, Dolcetti R, Doglioni C (2005) Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica 90:1578–1580PubMedGoogle Scholar
  14. 14.
    Sullivan TJ, Grimes D, Bunce I (2004) Monoclonal antibody treatment of orbital lymphoma. Ophthal Plast Reconstr Surg 20:103–106PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Luigi Rigacci
    • 1
    Email author
  • Luca Nassi
    • 1
  • Marco Puccioni
    • 2
  • Silvia Mappa
    • 1
  • Ennio Polito
    • 3
  • Serena Dal Pozzo
    • 2
  • Renato Alterini
    • 1
  • Valentina Carrai
    • 1
  • Benedetta Puccini
    • 1
  • Alberto Bosi
    • 1
  1. 1.Department of HematologyAzienda Ospedaliero-Universitaria CareggiFlorenceItaly
  2. 2.Department of OphthalmologyUniversity of FlorenceFlorenceItaly
  3. 3.Department of OphthalmologyPoliclinico Le Scotte and University of SienaSienaItaly

Personalised recommendations